Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapies

This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.

Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

The site in the US will produce CAR T-cell therapies for patients with blood cancers. ... CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment.

Latest news

More from news
Approximately 3 fully matching, plus 93 partially matching documents found.

Latest Intelligence

  • Charting patient pathways with precision for better healthcare Charting patient pathways with precision for better healthcare

    more as many of the parts don’t mesh together, are fitted at different times and operate across a crowded spectrum. ... We will see faster progress in areas such as CAR-T and gene therapies because these are personalised medicines and the patient is

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Historically, both large pharmaceutical and small biotechnology companies have relied on both internal and external sourcing of innovative and promising therapies. ... and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and

More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • White paper: Are we prepared for the influx of CAR-Ts?

    Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies. ... With CAR-Ts continuing to take centre stage as a paradigm shift in the treatment of cancer

  • The heavy toll of COVID-19 on cancer patients

    For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.

  • In the precision medicine era, the line between products and services is blurred

    Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.

  • Precision paediatrics: Treating patients with CAR-T

    It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.

  • Highlights in haematologic malignancy from ASH 2018

    However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....